Skip to content
2000
image of Elucidating the Potential Mechanism of Ulcerative Colitis Amelioration by Artemisia annua L. Based on Network Pharmacology and Experimental Validation

Abstract

Background

Ulcerative colitis (UC) is a chronic and recurrent enteritis requiring comprehensive treatment. L. () has shown a promising role in UC therapy, yet its key components and mechanisms of action are not fully understood.

Objective

This study aimed to investigate the effects of on UC, identify bioactive components, and elucidate underlying targets and mechanisms.

Materials and Methods

Candidate targets of components and UC targets were overlapped using the PPI network and GO and KEGG pathway enrichment analyses. Molecular docking, a DSS mouse model (BALB/c), and an LPS/IFNγ cell model were employed to validate the efficacy and mechanism of action of against UC.

Results

The -ingredient-target-UC network included 21 active components, 65 candidate targets, and 10 hub genes. Molecular docking showed excellent fitting of the top 9 active components in the binding pocket of the top 6 hub targets. A DSS mouse model and an LPS/IFNγ cell model revealed the weight loss, intestinal inflammation, the expressions of hub targets and critical inflammatory signaling pathways molecules (p-NFκB and p-STAT3) to be significantly attenuated by . Furthermore, significantly reduced intraepithelial bacteria, enhanced TEER, and decreased FITC-dextran permeability in animal and cellular experiments.

Conclusion

This study demonstrated the significant protective effects of against inflammation and its ability to preserve the integrity of the transcellular and paracellular intestinal epithelial barrier, suggesting a promising application of in UC prevention and therapy.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cchts/10.2174/0113862073424929250918114217
2025-10-09
2025-11-29

  • From This Site

    /content/journals/cchts/10.2174/0113862073424929250918114217
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Le Berre C. Honap S. Peyrin-Biroulet L. Ulcerative colitis. Lancet 2023 402 10401 571 584 10.1016/S0140‑6736(23)00966‑2 37573077
    [Google Scholar]
  2. Wangchuk P. Yeshi K. Loukas A. Ulcerative colitis: Clinical biomarkers, therapeutic targets, and emerging treatments. Trends Pharmacol. Sci. 2024 45 10 892 903 10.1016/j.tips.2024.08.003 39261229
    [Google Scholar]
  3. Gros B. Kaplan G.G. Ulcerative colitis in adults. JAMA 2023 330 10 951 965 10.1001/jama.2023.15389 37698559
    [Google Scholar]
  4. Zheng S. Xue T. Wang B. Guo H. Liu Q. Chinese medicine in the treatment of ulcerative colitis: The mechanisms of signaling pathway regulations. Am. J. Chin. Med. 2022 50 7 1781 1798 10.1142/S0192415X22500756 35950375
    [Google Scholar]
  5. Wang M Fu R Xu D Chen Y Yue S Zhang S Tang Y Traditional Chinese Medicine: A promising strategy to regulate the imbalance of bacterial flora, impaired intestinal barrier and immune function attributed to ulcerative colitis through intestinal microecology J. Ethnopharmacol 2024 318 Pt A 116879 116879 10.1016/j.jep.2023.116879 37419224
    [Google Scholar]
  6. Xing Q. Fu L. Yu Z. Zhou X. Efficacy and safety of integrated traditional chinese medicine and western medicine on the treatment of rheumatoid arthritis: A meta-analysis. Evid. Based Complement. Alternat. Med. 2020 2020 1 4348709 10.1155/2020/4348709 32328130
    [Google Scholar]
  7. Feng X. Cao S. Qiu F. Zhang B. Traditional application and modern pharmacological research of Artemisia annua L. Pharmacol. Ther. 2020 216 107650 10.1016/j.pharmthera.2020.107650 32758647
    [Google Scholar]
  8. Septembre-Malaterre A. Lalarizo Rakoto M. Marodon C. Bedoui Y. Nakab J. Simon E. Hoarau L. Savriama S. Strasberg D. Guiraud P. Selambarom J. Gasque P. Artemisia annua, a traditional plant brought to light. Int. J. Mol. Sci. 2020 21 14 4986 10.3390/ijms21144986 32679734
    [Google Scholar]
  9. Liang D. Yixuan D. Chang L. Jingjing S. Sihai Z. Jie D. Mechanism of Artemisia annua L. in the treatment of acute myocardial infarction: Network pharmacology, molecular docking and in vivo validation. Mol. Divers. 2024 28 5 3225 3242 10.1007/s11030‑023‑10750‑3 37898972
    [Google Scholar]
  10. Kim M.H. Seo J.Y. Liu K.H. Kim J.S. Protective effect of Artemisia annua L. extract against galactose-induced oxidative stress in mice. PLoS One 2014 9 7 e101486 10.1371/journal.pone.0101486 24988450
    [Google Scholar]
  11. Jin Q. Liu T. Chen D. Yang L. Mao H. Ma F. Wang Y. Li P. Zhan Y. Therapeutic potential of artemisinin and its derivatives in managing kidney diseases. Front. Pharmacol. 2023 14 1097206 10.3389/fphar.2023.1097206 36874000
    [Google Scholar]
  12. Efferth T. Oesch F. The immunosuppressive activity of artemisinin-type drugs towards inflammatory and autoimmune diseases. Med. Res. Rev. 2021 41 6 3023 3061 10.1002/med.21842 34288018
    [Google Scholar]
  13. Guo S. Shi B. Xing Y. Xu Y. Jin X. Hong L. Zhang S. Qiao M. Yan S. Artemisia annua L. polysaccharide improves the growth performance and intestinal barrier function of broilers challenged with Escherichia coli. Front. Microbiol. 2024 15 1390815 10.3389/fmicb.2024.1390815 38746748
    [Google Scholar]
  14. Sun W. Han X. Wu S. Wu J. Yang C. Li X. Unexpected mechanism of colitis amelioration by artesunate, a natural product from Artemisia annua L. Inflammopharmacology 2020 28 4 851 868 10.1007/s10787‑019‑00678‑2 31865495
    [Google Scholar]
  15. Lee A.S. Hur H.J. Sung M.J. The effect of artemisinin on inflammation-associated lymphangiogenesis in experimental acute colitis. Int. J. Mol. Sci. 2020 21 21 8068 10.3390/ijms21218068 33138094
    [Google Scholar]
  16. Chen J. Zhong H. Huang Z. Chen X. You J. Zou T. A critical review of kaempferol in intestinal health and diseases. Antioxidants 2023 12 8 1642 10.3390/antiox12081642 37627637
    [Google Scholar]
  17. Riemschneider S. Hoffmann M. Slanina U. Weber K. Hauschildt S. Lehmann J. Indol-3-carbinol and quercetin ameliorate chronic DSS-induced colitis in C57BL/6 mice by AhR-mediated anti-inflammatory mechanisms. Int. J. Environ. Res. Public Health 2021 18 5 2262 10.3390/ijerph18052262 33668818
    [Google Scholar]
  18. Meitei H.T. Jadhav N. Lal G. CCR6-CCL20 axis as a therapeutic target for autoimmune diseases. Autoimmun. Rev. 2021 20 7 102846 10.1016/j.autrev.2021.102846 33971346
    [Google Scholar]
  19. Cao G. Luo Q. Wu Y. Chen G. Inflammatory bowel disease and rheumatoid arthritis share a common genetic structure. Front. Immunol. 2024 15 1359857 10.3389/fimmu.2024.1359857 38938570
    [Google Scholar]
  20. Yang M. Guo M. Luo Y. Yun M. Yan J. Liu T. Xiao C. Effect of Artemisia annua extract on treating active rheumatoid arthritis: A randomized controlled trial. Chin. J. Integr. Med. 2017 23 7 496 503 10.1007/s11655‑016‑2650‑7 28035541
    [Google Scholar]
  21. Zhang Y. Qi Y. Jia Z. Li Y. Wu L. Zhou Q. Xu F. Effects and mechanisms of Zhizi Chuanxiong herb pair against atherosclerosis: An integration of network pharmacology, molecular docking, and experimental validation. Chin. Med. 2024 19 1 8 10.1186/s13020‑023‑00874‑x 38212797
    [Google Scholar]
  22. Mu B.X. Li Y. Ye N. Liu S. Zou X. Qian J. Wu C. Zhuang Y. Chen M. Zhou J.Y. Understanding apoptotic induction by Sargentodoxa cuneata-Patrinia villosa herb pair via PI3K/AKT/mTOR signalling in colorectal cancer cells using network pharmacology and cellular studies. J. Ethnopharmacol. 2024 319 Pt 3 117342 10.1016/j.jep.2023.117342 37879505
    [Google Scholar]
  23. Ru J. Li P. Wang J. Zhou W. Li B. Huang C. Li P. Guo Z. Tao W. Yang Y. Xu X. Li Y. Wang Y. Yang L. TCMSP: A database of systems pharmacology for drug discovery from herbal medicines. J. Cheminform. 2014 6 1 13 10.1186/1758‑2946‑6‑13 24735618
    [Google Scholar]
  24. Li H. Li W. Wu Y. Wu H. Cai X. Integrating network pharmacology and animal experimental validation to investigate the mechanism of lotus leaf in obesity. Int. Immunopharmacol. 2025 145 113719 10.1016/j.intimp.2024.113719 39647284
    [Google Scholar]
  25. Jiang M. Zhong G. Zhu Y. Wang L. He Y. Sun Q. Wu X. You X. Gao S. Tang D. Wang D. Retardant effect of dihydroartemisinin on ulcerative colitis in a JAK2/STAT3-dependent manner. Acta Biochim. Biophys. Sin. 2021 53 9 1113 1123 10.1093/abbs/gmab097 34259316
    [Google Scholar]
  26. Lei Z. Yang Y. Liu S. Lei Y. Yang L. Zhang X. Liu W. Wu H. Yang C. Guo J. Dihydroartemisinin ameliorates dextran sulfate sodium induced inflammatory bowel diseases in mice. Bioorg. Chem. 2020 100 103915 10.1016/j.bioorg.2020.103915 32450383
    [Google Scholar]
  27. Pai Y.C. Weng L.T. Wei S.C. Wu L.L. Shih D.Q. Targan S.R. Turner J.R. Yu L.C. Gut microbial transcytosis induced by tumor necrosis factor-like 1A-dependent activation of a myosin light chain kinase splice variant contributes to IBD. J. Crohn’s Colitis 2021 15 2 258 272 10.1093/ecco‑jcc/jjaa165 32770194
    [Google Scholar]
  28. Grossmann J. Walther K. Artinger M. Kiessling S. Steinkamp M. Schmautz W.K. Stadler F. Bataille F. Schultz M. Schölmerich J. Rogler G. Progress on isolation and short-term ex-vivo culture of highly purified non-apoptotic human intestinal epithelial cells (IEC). Eur. J. Cell Biol. 2003 82 5 262 270 10.1078/0171‑9335‑00312 12800981
    [Google Scholar]
  29. Wu L.L. Peng W.H. Kuo W.T. Huang C.Y. Ni Y.H. Lu K.S. Turner J.R. Yu L.C.H. Commensal bacterial endocytosis in epithelial cells is dependent on myosin light chain kinase-activated brush border fanning by interferon-γ. Am. J. Pathol. 2014 184 8 2260 2274 10.1016/j.ajpath.2014.05.003 24911373
    [Google Scholar]
  30. Yu L.C.H. Shih Y.A. Wu L.L. Lin Y.D. Kuo W.T. Peng W.H. Lu K.S. Wei S.C. Turner J.R. Ni Y.H. Enteric dysbiosis promotes antibiotic-resistant bacterial infection: Systemic dissemination of resistant and commensal bacteria through epithelial transcytosis. Am. J. Physiol. Gastrointest. Liver Physiol. 2014 307 8 G824 G835 10.1152/ajpgi.00070.2014 25059827
    [Google Scholar]
  31. Srinivasan B. Kolli A.R. Esch M.B. Abaci H.E. Shuler M.L. Hickman J.J. TEER measurement techniques for in vitro barrier model systems. SLAS Technol. 2015 20 2 107 126 10.1177/2211068214561025 25586998
    [Google Scholar]
  32. Lin J.C. Wu J.Q. Wang F. Tang F.Y. Sun J. Xu B. Jiang M. Chu Y. Chen D. Li X. Su S. Zhang Y. Wu N. Yang S. Wu K. Liang J. QingBai decoction regulates intestinal permeability of dextran sulphate sodium-induced colitis through the modulation of notch and NF‐κB signalling. Cell Prolif. 2019 52 2 e12547 10.1111/cpr.12547 30657238
    [Google Scholar]
  33. Clark E. Hoare C. Tanianis-Hughes J. Carlson G.L. Warhurst G. Interferon gamma induces translocation of commensal Escherichia coli across gut epithelial cells via a lipid raft-mediated process. Gastroenterology 2005 128 5 1258 1267 10.1053/j.gastro.2005.01.046 15887109
    [Google Scholar]
  34. Twinomujuni S.S. Atukunda E.C. Mukonzo J.K. Nicholas M. Roelofsen F. Ogwang P.E. Evaluation of the effects of Artemisia Annua L. and Moringa Oleifera Lam. on CD4 count and viral load among PLWH on ART at Mbarara Regional Referral Hospital: A double-blind randomized controlled clinical trial. AIDS Res. Ther. 2024 21 1 22 10.1186/s12981‑024‑00609‑4 38627722
    [Google Scholar]
  35. Gao X. Lin X. Wang Q. Chen J. Artemisinins: Promising drug candidates for the treatment of autoimmune diseases. Med. Res. Rev. 2024 44 2 867 891 10.1002/med.22001 38054758
    [Google Scholar]
  36. Bergemalm D. Andersson E. Hultdin J. Eriksson C. Rush S.T. Kalla R. Adams A.T. Keita Å.V. D’Amato M. Gomollon F. Jahnsen J. Ricanek P. Satsangi J. Repsilber D. Karling P. Halfvarson J. Arnott I.D. Bayes M. Bonfiglio F. Boyapati R.K. Carstens A. Casén C. Ciemniejewska E. Dahl F.A. Detlie T.E. Drummond H.E. Ekeland G.S. Ekman D. Frengen A.B. Gullberg M. Gut I.G. Gut M. Heath S.C. Hjelm F. Hjortswang H. Ho G-T. Jonkers D. Söderholm J. Kennedy N.A. Lees C.W. Lindahl T. Lindqvist M. Merkel A. Modig E. Moen A.E.F. Nilsen H. Nimmo E.R. Noble C.L. Nordberg N. O’Leary K.R. Ocklind A. Olbjørn C. Pettersson E. Pierik M. Dominique, Systemic inflammation in preclinical ulcerative colitis. Gastroenterology 2021 161 5 1526 1539.e9 10.1053/j.gastro.2021.07.026 34298022
    [Google Scholar]
  37. Rodríguez-Lago I. Ramírez C. Merino O. Azagra I. Maiz A. Zapata E. Higuera R. Montalvo I. Fernández-Calderón M. Arreba P. Carrascosa J. Iriarte A. Muñoz-Navas M. Cabriada J.L. Barreiro-de Acosta M. Early microscopic findings in preclinical inflammatory bowel disease. Dig. Liver Dis. 2020 52 12 1467 1472 10.1016/j.dld.2020.05.052 32601034
    [Google Scholar]
  38. Zamuner S.R. Warrier N. Buret A.G. MacNaughton W.K. Wallace J.L. Cyclooxygenase 2 mediates post-inflammatory colonic secretory and barrier dysfunction. Gut 2003 52 12 1714 1720 10.1136/gut.52.12.1714 14633948
    [Google Scholar]
  39. Foell D. Kucharzik T. Kraft M. Vogl T. Sorg C. Domschke W. Roth J. Neutrophil derived human S100A12 (EN-RAGE) is strongly expressed during chronic active inflammatory bowel disease. Gut 2003 52 6 847 853 10.1136/gut.52.6.847 12740341
    [Google Scholar]
  40. Hofmann M.A. Drury S. Fu C. Qu W. Taguchi A. Lu Y. Avila C. Kambham N. Bierhaus A. Nawroth P. Neurath M.F. Slattery T. Beach D. McClary J. Nagashima M. Morser J. Stern D. Schmidt A.M. RAGE mediates a novel proinflammatory axis: A central cell surface receptor for S100/calgranulin polypeptides. Cell 1999 97 7 889 901 10.1016/S0092‑8674(00)80801‑6 10399917
    [Google Scholar]
  41. Fröhling M. Tepasse P. Intemann J. Sambale M. Sherwood J. Paruzel P. Tiemeyer N.M. Nowacki T.M. Brückner M. Mennigen R. Lügering A. Echtermeyer F. Pap T. Stratis A. Bettenworth D. Syndecan-4 modulates epithelial gut barrier function and epithelial regeneration in experimental colitis. Inflamm. Bowel Dis. 2018 24 12 2579 2589 10.1093/ibd/izy248 30053064
    [Google Scholar]
  42. Shinyuy L.M. Loe G.E. Jansen O. Mamede L. Ledoux A. Noukimi S.F. Abenwie S.N. Ghogomu S.M. Souopgui J. Robert A. Demeyer K. Frederich M. Secondary metabolites isolated from Artemisia afra and Artemisia annua and their anti-malarial, anti-inflammatory and immunomodulating properties - Pharmacokinetics and pharmacodynamics: A review. Metabolites 2023 13 5 613 10.3390/metabo13050613 37233654
    [Google Scholar]
  43. Stebbings S. Beattie E. McNamara D. Hunt S. A pilot randomized, placebo-controlled clinical trial to investigate the efficacy and safety of an extract of Artemisia annua administered over 12 weeks, for managing pain, stiffness, and functional limitation associated with osteoarthritis of the hip and knee. Clin. Rheumatol. 2016 35 7 1829 1836 10.1007/s10067‑015‑3110‑z 26631103
    [Google Scholar]
  44. Rassias D.J. Weathers P.J. Dried leaf Artemisia annua efficacy against non-small cell lung cancer. Phytomedicine 2019 52 247 253 10.1016/j.phymed.2018.09.167 30599905
    [Google Scholar]
/content/journals/cchts/10.2174/0113862073424929250918114217
Loading
Elucidating the Potential Mechanism of Ulcerative Colitis Amelioration by Artemisia annua L. Based on Network Pharmacology and Experimental Validation
Bentham Science Publishers ; https://doi.org/10.2174/0113862073424929250918114217
/content/journals/cchts/10.2174/0113862073424929250918114217
/content/journals/cchts/10.2174/0113862073424929250918114217
Loading

Data & Media loading...

Supplements

Supplementary material is available on the publisher's website along with the published article.

file format download Download

  • Article Type:     Research Article
Keywords: network pharmacology ; inflammation ; Chinese medicine ; intestinal epithelial barrier injury ; Artemisia annua L. ; ulcerative colitis

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test